Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies
Methods: A total of 75,422 participants in the Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) study were screened for MGUS with serum protein electrophoresis (SPEP), serum free light chains (FLC), and immunofixation (IFE). All previous clinical laboratory samples were obtained, including serum creatinine (SCr), urine albumin/creatinine ratio (ACR) and urinalysis. CKD was defined as SCr-based eGFR of <60 mL/min/1.73m2, or proteinuria or hematuria, present for >90 days. Participants diagnosed with lymphoproliferative disorders or without data on kidney function were excluded. Power analysis demonstrated that this sample size yielded 90% power to detect a 1.5% absolute difference in the prevalence of CKD in persons with and without MGUS. Prevalence of CKD was evaluated using multivariable logistic regression adjusted for age, sex and MGUS status. The association between eGFR and M protein concentration was assessed with linear regression for continuous eGFR and ordinal logistic regression for CKD categories. All models included age and M protein concentration as four knot restricted cubic splines. Sensitivity analyses were performed where CKD was defined solely by persistently lowered eGFR and as a combination of persistently lowered eGFR, proteinuria, and hematuria.
Results: A total of 69,120 participants had SCr measurements and 34,294 had urine studies available. MGUS was present in 4,547 (6.6%) participants, of which 2,242 (49.3%) were non-IgM; 703 (15.5%) were IgM; 1,295 (28.5%) were light chain (LC-MGUS); and 307 (6.7%) were biclonal MGUS. A total of 6,680 (9.7%) participants had CKD defined either as eGFR <60 mL/min/1.73 m2 (N=5,915) or persistent proteinuria or hematuria (N=693), or were receiving treatment for end-stage kidney disease (N=74). Participants with MGUS were significantly older (median [IQR] age 69 [60-76] vs 60 [52-69] years) and more predominantly male (55% vs 41%) compared with participants without MGUS. After adjusting for age and sex, no significant association was found between heavy chain MGUS and CKD (odds ratio [OR] 1.00, 95% confidence interval [CI] 0.95–1.17). This also remained true for subgroups of non-IgM MGUS, IgM MGUS, and biclonal MGUS (Table). Participants with LC-MGUS were less likely to have CKD than participants without MGUS (OR 0.39, 95% CI 0.31–0.49, p <0.001). Sensitivity analyses of CKD definition yielded similar results. M protein concentration had a small negative correlation with eGFR (r= -0.08, p<0.001) but when stratified by age and sex category no significant correlation remained. No significant association was found between M protein concentration and worse eGFR category on ordinal logistic regression model adjusted for nonlinear age and sex (OR 1.01, 95% CI, 0.28–3.66). No significant correlation was found between M protein concentration and severity of proteinuria assessed with urine ACR.
Conclusion: In this nationwide prospective population-based screening study of nearly 70,000 individuals, we found no association between MGUS and CKD, regardless of whether CKD was defined based on eGFR, urinary findings, or both. Furthermore, we found no association between M protein concentration and eGFR or severity of albuminuria. We conclude that in the absence of multiple myeloma, the results of SPEP, IFE, and serum FLC measurements are of little value in the evaluation of CKD. Furthermore, our results are not consistent with substantial underdiagnosis of MGRS.
Disclosures: Onundarson: Fiix prothrombin time.: Patents & Royalties. Hultcrantz: Amgen, Daichii Sankyo, Cosette, GSK: Research Funding; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Curio Science LLC: Consultancy; Intellisphere LLC: Consultancy; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees. Durie: Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Harding: The Binding Site: Current Employment, Membership on an entity's Board of Directors or advisory committees. Landgren: Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Pfizer: Consultancy; Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Amgen: Research Funding. Kristinsson: Amgen: Research Funding; Celgene: Research Funding.
See more of: Oral and Poster Abstracts